The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug ...

The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Biden-era ...

Expansion of the Medicare drug price negotiation rare disease drug carve-out would unnecessarily limit the number of drugs ...

IRA’s $2,000 out-of-pocket cap helps few; most won’t hit the threshold Insurers raise deductibles, replace flat co-pays with costlier coinsurance ...

The sweeping One Big Beautiful Bill Act, signed into federal law July 4, amended CMS’ drug price negotiations authority that could absolve nearly $5 billion in projected savings, according to the ...

The House passed the “One Big Beautiful Bill Act” on July 3, which includes sweeping changes to healthcare and some pharma-related provisions.

President Donald Trump’s One Big Beautiful Bill, signed into law last week, reintroduces broader exemptions for orphan drugs from the IRA’s drug price negotiation program—a move welcomed by the ...

Risks to BMY include potential for tariffs to raise costs of drugs manufactured outside of the U.S. Moreover, drug pricing ...

Americans have been clamoring for sensible prescription drug reform for years. With the stroke of his pen, President Donald ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

The US government, seeking to fend off a drugmaker’s legal challenge over a federal drug price negotiation program, is ...

Mehmet Oz recently took the reins as the new head of the Centers for Medicare and Medicaid Services, which oversees health ...